

List of Publications by Year  
in descending order

Source: <https://exaly.com/author-pdf/684794/publications.pdf>

Version: 2024-02-01

189  
papers

20,353  
citations

18482

62  
h-index

11052

137  
g-index

197  
all docs

197  
docs citations

197  
times ranked

26516  
citing authors

#	ARTICLE	IF	CITATIONS
1	Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. <i>Nature Medicine</i> , 2004, 10, 942-949.	30.7	4,442
2	Intratumoral T Cells, Recurrence, and Survival in Epithelial Ovarian Cancer. <i>New England Journal of Medicine</i> , 2003, 348, 203-213.	27.0	2,930
3	ER Stress Sensor XBP1 Controls Anti-tumor Immunity by Disrupting Dendritic Cell Homeostasis. <i>Cell</i> , 2015, 161, 1527-1538.	28.9	639
4	Synthetic lethality by targeting EZH2 methyltransferase activity in ARID1A-mutated cancers. <i>Nature Medicine</i> , 2015, 21, 231-238.	30.7	530
5	Tumor-associated neutrophils stimulate T cell responses in early-stage human lung cancer. <i>Journal of Clinical Investigation</i> , 2014, 124, 5466-5480.	8.2	483
6	Cooperation between Constitutive and Inducible Chemokines Enables T Cell Engraftment and Immune Attack in Solid Tumors. <i>Cancer Cell</i> , 2019, 35, 885-900.e10.	16.8	475
7	Tumor-infiltrating dendritic cell precursors recruited by a $\beta$ -defensin contribute to vasculogenesis under the influence of Vegf-A. <i>Nature Medicine</i> , 2004, 10, 950-958.	30.7	431
8	Identification of a novel, multifunctional $\alpha$ -defensin (human $\alpha$ -defensin 3) with specific antimicrobial activity. <i>Cell and Tissue Research</i> , 2001, 306, 257-264.	2.9	371
9	Dysregulated Microbial Fermentation of Soluble Fiber Induces Cholestatic Liver Cancer. <i>Cell</i> , 2018, 175, 679-694.e22.	28.9	344
10	BET Bromodomain Inhibition Promotes Anti-tumor Immunity by Suppressing PD-L1 Expression. <i>Cell Reports</i> , 2016, 16, 2829-2837.	6.4	331
11	Origin and Role of a Subset of Tumor-Associated Neutrophils with Antigen-Presenting Cell Features in Early-Stage Human Lung Cancer. <i>Cancer Cell</i> , 2016, 30, 120-135.	16.8	311
12	Safety and Efficacy of Intratumoral Injections of Chimeric Antigen Receptor (CAR) T Cells in Metastatic Breast Cancer. <i>Cancer Immunology Research</i> , 2017, 5, 1152-1161.	3.4	309
13	Tumor-Intrinsic PD-L1 Signals Regulate Cell Growth, Pathogenesis, and Autophagy in Ovarian Cancer and Melanoma. <i>Cancer Research</i> , 2016, 76, 6964-6974.	0.9	294
14	Ovarian cancer progression is controlled by phenotypic changes in dendritic cells. <i>Journal of Experimental Medicine</i> , 2012, 209, 495-506.	8.5	273
15	Age Correlates with Response to Anti-PD1, Reflecting Age-Related Differences in Intratumoral Effector and Regulatory T-Cell Populations. <i>Clinical Cancer Research</i> , 2018, 24, 5347-5356.	7.0	253
16	IRE1 $\alpha$ -XBP1 controls T cell function in ovarian cancer by regulating mitochondrial activity. <i>Nature</i> , 2018, 562, 423-428.	27.8	252
17	Microbially Driven TLR5-Dependent Signaling Governs Distal Malignant Progression through Tumor-Promoting Inflammation. <i>Cancer Cell</i> , 2015, 27, 27-40.	16.8	242
18	Vascular leukocytes contribute to tumor vascularization. <i>Blood</i> , 2005, 105, 679-681.	1.4	183

#	ARTICLE	IF	CITATIONS
19	Polyethylenimine-based siRNA nanocomplexes reprogram tumor-associated dendritic cells via TLR5 to elicit therapeutic antitumor immunity. <i>Journal of Clinical Investigation</i> , 2009, 119, 2231-44.	8.2	177
20	ARID1A-mutated ovarian cancers depend on HDAC6 activity. <i>Nature Cell Biology</i> , 2017, 19, 962-973.	10.3	173
21	Tumor-infiltrating lymphocyte treatment for anti-PD-1-resistant metastatic lung cancer: a phase 1 trial. <i>Nature Medicine</i> , 2021, 27, 1410-1418.	30.7	168
22	Isolation and biochemical characterization of LEAP-2, a novel blood peptide expressed in the liver. <i>Protein Science</i> , 2003, 12, 143-152.	7.6	161
23	Local hyperthermia treatment of tumors induces CD8+ T cell-mediated resistance against distal and secondary tumors. <i>Nanomedicine: Nanotechnology, Biology, and Medicine</i> , 2014, 10, 1273-1285.	3.3	156
24	Tumor Cell-Independent Estrogen Signaling Drives Disease Progression through Mobilization of Myeloid-Derived Suppressor Cells. <i>Cancer Discovery</i> , 2017, 7, 72-85.	9.4	153
25	Reprogramming Tumor-Associated Dendritic Cells <i>In Vivo</i> Using miRNA Mimetics Triggers Protective Immunity against Ovarian Cancer. <i>Cancer Research</i> , 2012, 72, 1683-1693.	0.9	137
26	Tumor interferon signaling and suppressive myeloid cells are associated with CAR T-cell failure in large B-cell lymphoma. <i>Blood</i> , 2021, 137, 2621-2633.	1.4	137
27	Syndecan-1 expression is up-regulated in pancreatic but not in other gastrointestinal cancers. <i>International Journal of Cancer</i> , 2000, 88, 12-20.	5.1	130
28	Generation of a Syngeneic Mouse Model to Study the Effects of Vascular Endothelial Growth Factor in Ovarian Carcinoma. <i>American Journal of Pathology</i> , 2002, 161, 2295-2309.	3.8	129
29	Exosomes Produced by Mesenchymal Stem Cells Drive Differentiation of Myeloid Cells into Immunosuppressive M2-Polarized Macrophages in Breast Cancer. <i>Journal of Immunology</i> , 2019, 203, 3447-3460.	0.8	126
30	<i>In situ</i> Stimulation of CD40 and Toll-like Receptor 3 Transforms Ovarian Cancer-Infiltrating Dendritic Cells from Immunosuppressive to Immunostimulatory Cells. <i>Cancer Research</i> , 2009, 69, 7329-7337.	0.9	124
31	Mesothelin, a novel immunotherapy target for triple negative breast cancer. <i>Breast Cancer Research and Treatment</i> , 2012, 133, 799-804.	2.5	123
32	SATB1 Expression Governs Epigenetic Repression of PD-1 in Tumor-Reactive T Cells. <i>Immunity</i> , 2017, 46, 51-64.	14.3	122
33	HSV oncolytic therapy upregulates interferon-inducible chemokines and recruits immune effector cells in ovarian cancer. <i>Molecular Therapy</i> , 2005, 12, 789-802.	8.2	119
34	BET Inhibitors Suppress ALDH Activity by Targeting ALDH1A1 Super-Enhancer in Ovarian Cancer. <i>Cancer Research</i> , 2016, 76, 6320-6330.	0.9	115
35	Structure determination of human and murine beta-defensins reveals structural conservation in the absence of significant sequence similarity. <i>Protein Science</i> , 2001, 10, 2470-2479.	7.6	115
36	Antioxidant nutrients protect against cyclosporine A nephrotoxicity. <i>Toxicology</i> , 2003, 189, 99-111.	4.2	108

#	ARTICLE	IF	CITATIONS
37	The role of dendritic cell precursors in tumour vasculogenesis. British Journal of Cancer, 2005, 92, 1182-1187.	6.4	108
38	The Unfolded Protein Response Mediator PERK Governs Myeloid Cell-Driven Immunosuppression in Tumors through Inhibition of STING Signaling. Immunity, 2020, 52, 668-682.e7.	14.3	107
39	Depletion of Dendritic Cells Delays Ovarian Cancer Progression by Boosting Antitumor Immunity. Cancer Research, 2008, 68, 7684-7691.	0.9	105
40	Distribution of new human $\beta$ -defensin genes clustered on chromosome 20 in functionally different segments of epididymis. Genomics, 2003, 81, 175-183.	2.9	104
41	Fluorescence-Based Codetection with Protein Markers Reveals Distinct Cellular Compartments for Altered MicroRNA Expression in Solid Tumors. Clinical Cancer Research, 2010, 16, 4246-4255.	7.0	102
42	Transforming Growth Factor $\beta$ -Mediated Suppression of Antitumor T Cells Requires FoxP1 Transcription Factor Expression. Immunity, 2014, 41, 427-439.	14.3	100
43	IgA transcytosis and antigen recognition govern ovarian cancer immunity. Nature, 2021, 591, 464-470.	27.8	99
44	Chimeric NKG2D Receptor-Bearing T Cells as Immunotherapy for Ovarian Cancer. Cancer Research, 2007, 67, 5003-5008.	0.9	96
45	Satb1 Overexpression Drives Tumor-Promoting Activities in Cancer-Associated Dendritic Cells. Cell Reports, 2016, 14, 1774-1786.	6.4	89
46	NK-1 receptor gene expression is related to pain in chronic pancreatitis. Pain, 2001, 91, 209-217.	4.2	88
47	Avirulent <i>Toxoplasma gondii</i> Generates Therapeutic Antitumor Immunity by Reversing Immunosuppression in the Ovarian Cancer Microenvironment. Cancer Research, 2013, 73, 3842-3851.	0.9	86
48	Scavenger Receptor-Targeted Leukocyte Depletion Inhibits Peritoneal Ovarian Tumor Progression. Cancer Research, 2007, 67, 4783-4789.	0.9	85
49	Tumor cell-intrinsic PD-L1 promotes tumor-initiating cell generation and functions in melanoma and ovarian cancer. Signal Transduction and Targeted Therapy, 2016, 1, .	17.1	83
50	ER stress-induced mediator C/EBP homologous protein thwarts effector T cell activity in tumors through T-bet repression. Nature Communications, 2019, 10, 1280.	12.8	83
51	BTN3A1 governs antitumor responses by coordinating $\beta$ and $\gamma$ T cells. Science, 2020, 369, 942-949.	12.6	83
52	Oncolytic HSV Exerts Direct Antiangiogenic Activity in Ovarian Carcinoma. Human Gene Therapy, 2005, 16, 765-778.	2.7	81
53	Follicle-Stimulating Hormone Receptor Is Expressed by Most Ovarian Cancer Subtypes and Is a Safe and Effective Immunotherapeutic Target. Clinical Cancer Research, 2017, 23, 441-453.	7.0	77
54	Repurposing Pan-HDAC Inhibitors for ARID1A-Mutated Ovarian Cancer. Cell Reports, 2018, 22, 3393-3400.	6.4	77

#	ARTICLE	IF	CITATIONS
55	Telomeric repeat-containing RNA (TERRA) constitutes a nucleoprotein component of extracellular inflammatory exosomes. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2015, 112, E6293-300.	7.1	76
56	CD4+ T Cells Elicit Host Immune Responses to MHC Class II $\alpha$ Ovarian Cancer through CCL5 Secretion and CD40-Mediated Licensing of Dendritic Cells. <i>Journal of Immunology</i> , 2010, 184, 5654-5662.	0.8	75
57	Fibroblast activation protein expression by stromal cells and tumor-associated macrophages in human breast cancer. <i>Human Pathology</i> , 2013, 44, 2549-2557.	2.0	75
58	Three-dimensional culture sensitizes epithelial ovarian cancer cells to EZH2 methyltransferase inhibition. <i>Cell Cycle</i> , 2013, 12, 2113-2119.	2.6	74
59	CARM1-expressing ovarian cancer depends on the histone methyltransferase EZH2 activity. <i>Nature Communications</i> , 2018, 9, 631.	12.8	72
60	Frontline Science: Microbiota reconstitution restores intestinal integrity after cisplatin therapy. <i>Journal of Leukocyte Biology</i> , 2018, 103, 799-805.	3.3	72
61	Sirt2 Inhibition Enhances Metabolic Fitness and Effector Functions of Tumor-Reactive T Cells. <i>Cell Metabolism</i> , 2020, 32, 420-436.e12.	16.2	72
62	Shaping the Immune Landscape in Cancer by Galectin-Driven Regulatory Pathways. <i>Journal of Molecular Biology</i> , 2016, 428, 3266-3281.	4.2	67
63	Different Effects of Glucose Starvation on Expression and Stability of VEGF mRNA Isoforms in Murine Ovarian Cancer Cells. <i>Biochemical and Biophysical Research Communications</i> , 2002, 292, 860-868.	2.1	65
64	Macrophages infiltrating the tissue in chronic pancreatitis express the chemokine receptor CCR5. <i>Surgery</i> , 2000, 128, 806-814.	1.9	64
65	Ovarian Carcinoma Expresses the NKG2D Ligand <i>Letal</i> and Promotes the Survival and Expansion of CD28 $\alpha$ Antitumor T Cells. <i>Cancer Research</i> , 2004, 64, 2175-2182.	0.9	64
66	Effects of Tobacco Smoking on the Tumor Immune Microenvironment in Head and Neck Squamous Cell Carcinoma. <i>Clinical Cancer Research</i> , 2020, 26, 1474-1485.	7.0	62
67	CD277 is a Negative Co-stimulatory Molecule Universally Expressed by Ovarian Cancer Microenvironmental Cells. <i>Oncotarget</i> , 2010, 1, 329-338.	1.8	62
68	TGF- $\beta$ 2-mediated silencing of genomic organizer SATB1 promotes Tfh cell differentiation and formation of intra-tumoral tertiary lymphoid structures. <i>Immunity</i> , 2022, 55, 115-128.e9.	14.3	62
69	Use of immuno-LCM to identify the in situ expression profile of cellular constituents of the tumor microenvironment. <i>Cancer Biology and Therapy</i> , 2006, 5, 635-642.	3.4	60
70	Formation of telomeric repeat-containing RNA (TERRA) foci in highly proliferating mouse cerebellar neuronal progenitors and medulloblastoma. <i>Journal of Cell Science</i> , 2012, 125, 4383-94.	2.0	58
71	Targeted Therapy and Immunosuppression in the Tumor Microenvironment. <i>Trends in Cancer</i> , 2017, 3, 19-27.	7.4	57
72	CCL5-Mediated Endogenous Antitumor Immunity Elicited by Adoptively Transferred Lymphocytes and Dendritic Cell Depletion. <i>Cancer Research</i> , 2009, 69, 6331-6338.	0.9	56

#	ARTICLE	IF	CITATIONS
73	Identifying alemtuzumab as an anti-myeloid cell antiangiogenic therapy for the treatment of ovarian cancer. <i>Journal of Translational Medicine</i> , 2009, 7, 49.	4.4	56
74	LETAL, A Tumor-Associated NKG2D Immunoreceptor Ligand, Induces Activation and Expansion of Effector Immune Cells. <i>Cancer Biology and Therapy</i> , 2003, 2, 446-451.	3.4	55
75	CYCLOSPORINE INCREASES LOCAL GLOMERULAR SYNTHESIS OF REACTIVE OXYGEN SPECIES IN RATS1. <i>Transplantation</i> , 1998, 66, 1325-1329.	1.0	55
76	Targeting the Tumor Stroma as a Novel Treatment Strategy for Breast Cancer. <i>Advances in Pharmacology</i> , 2012, 65, 45-61.	2.0	53
77	Ovarian cancer immunogenicity is governed by a narrow subset of progenitor tissue-resident memory T <sub>H</sub> 1 cells. <i>Cancer Cell</i> , 2022, 40, 545-557.e13.	16.8	53
78	B cells and cancer. <i>Cancer Cell</i> , 2021, 39, 1293-1296.	16.8	52
79	A role for the chemokine receptor CCR6 in mammalian sperm motility and chemotaxis. <i>Journal of Cellular Physiology</i> , 2013, 229, n/a-n/a.	4.1	49
80	The Tumor Microenvironment. <i>Advances in Cancer Research</i> , 2015, 128, 235-262.	5.0	48
81	Trametinib Drives T-cell-Dependent Control of KRAS-Mutated Tumors by Inhibiting Pathological Myelopoiesis. <i>Cancer Research</i> , 2016, 76, 6253-6265.	0.9	46
82	<i>Mycobacterium tuberculosis</i> infection induces <i>IL12RB1</i> splicing to generate a novel IL-12R $\beta$ 1 isoform that enhances DC migration. <i>Journal of Experimental Medicine</i> , 2010, 207, 591-605.	8.5	44
83	State-of-the-art of regulatory dendritic cells in cancer. , 2016, 164, 97-104.		43
84	Phagocytes mediate targeting of iron oxide nanoparticles to tumors for cancer therapy. <i>Integrative Biology (United Kingdom)</i> , 2013, 5, 159-171.	1.3	42
85	Mesothelin expression is associated with poor outcomes in breast cancer. <i>Breast Cancer Research and Treatment</i> , 2014, 147, 675-684.	2.5	42
86	Blocking ovarian cancer progression by targeting tumor microenvironmental leukocytes. <i>Cell Cycle</i> , 2010, 9, 260-268.	2.6	41
87	Mast cells impair the development of protective anti-tumor immunity. <i>Cancer Immunology, Immunotherapy</i> , 2012, 61, 2273-2282.	4.2	39
88	PD-1/PD-L1 immune checkpoint inhibitors in advanced cervical cancer. <i>Integrative Cancer Science and Therapeutics</i> , 2018, 5, .	0.1	38
89	PILAR is a novel modulator of human T-cell expansion. <i>Blood</i> , 2008, 112, 1259-1268.	1.4	37
90	AMPK Alpha-1 Intrinsically Regulates the Function and Differentiation of Tumor Myeloid-Derived Suppressor Cells. <i>Cancer Research</i> , 2019, 79, 5034-5047.	0.9	37

#	ARTICLE	IF	CITATIONS
91	Prospective Single-Arm Phase 1 and 2 Study: Ipilimumab and Nivolumab With Thoracic Radiation Therapy After Platinum Chemotherapy in Extensive-Stage Small Cell Lung Cancer. International Journal of Radiation Oncology Biology Physics, 2021, 109, 425-435.	0.8	35
92	Molecular adjuvant IL-33 enhances the potency of a DNA vaccine in a lethal challenge model. Vaccine, 2015, 33, 4313-4320.	3.8	33
93	Estimation of immune cell content in tumor using single-cell RNA-seq reference data. BMC Cancer, 2019, 19, 715.	2.6	32
94	Immunotherapy for gynaecological malignancies. Expert Opinion on Biological Therapy, 2005, 5, 1193-1210.	3.1	31
95	Immunotherapy for Breast Cancer: Current and Future Strategies. Current Surgery Reports, 2017, 5, 1.	0.9	31
96	Interaction of bacterial genera associated with therapeutic response to immune checkpoint PD-1 blockade in a United States cohort. Genome Medicine, 2022, 14, 35.	8.2	29
97	Does the F508-CFTR mutation induce a proinflammatory response in human airway epithelial cells?. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2012, 303, L509-L518.	2.9	28
98	Constitutively activated PI3K accelerates tumor initiation and modifies histopathology of breast cancer. Oncogenesis, 2016, 5, e267-e267.	4.9	28
99	ORIGINAL ARTICLE: Human Uterine NK Cells Interact with Uterine Macrophages via NKG2D upon Stimulation with PAMPs. American Journal of Reproductive Immunology, 2009, 61, 52-61.	1.2	26
100	IL15 Agonists Overcome the Immunosuppressive Effects of MEK Inhibitors. Cancer Research, 2016, 76, 2561-2572.	0.9	26
101	Real-Time Quantitative PCR of Telomerase mRNA Is Useful for the Differentiation of Benign and Malignant Pancreatic Disorders. Pancreas, 2001, 22, 331-340.	1.1	25
102	Preparation of apoptotic tumor cells with replication-incompetent HSV augments the efficacy of dendritic cell vaccines. Cancer Gene Therapy, 2006, 13, 182-193.	4.6	24
103	Galectin-1 is essential for the induction of MOG <sub>35-55</sub> -based intravenous tolerance in experimental autoimmune encephalomyelitis. European Journal of Immunology, 2016, 46, 1783-1796.	2.9	24
104	Pathological Mobilization and Activities of Dendritic Cells in Tumor-Bearing Hosts: Challenges and Opportunities for Immunotherapy of Cancer. Frontiers in Immunology, 2013, 4, 435.	4.8	23
105	The Primary Effect on the Proteome of ARID1A-mutated Ovarian Clear Cell Carcinoma is Downregulation of the Mevalonate Pathway at the Post-transcriptional Level. Molecular and Cellular Proteomics, 2016, 15, 3348-3360.	3.8	23
106	Tumor Intrinsic PD-L1 Promotes DNA Repair in Distinct Cancers and Suppresses PARP Inhibitor-Induced Synthetic Lethality. Cancer Research, 2022, 82, 2156-2170.	0.9	23
107	Interference from lipemia in cell count by hematology analyzers. Clinical Chemistry, 1996, 42, 987-988.	3.2	22
108	CD122-Selective IL2 Complexes Reduce Immunosuppression, Promote Treg Fragility, and Sensitize Tumor Response to PD-L1 Blockade. Cancer Research, 2020, 80, 5063-5075.	0.9	21



#	ARTICLE	IF	CITATIONS
109	IgA-Dominated Humoral Immune Responses Govern Patients' Outcome in Endometrial Cancer. Cancer Research, 2022, 82, 859-871.	0.9	21
110	Direct vaccination with tumor cells killed with ICP4-deficient HSVd120 elicits effective antitumor immunity. Cancer Biology and Therapy, 2006, 5, 867-874.	3.4	20
111	Initiation of Metastatic Breast Carcinoma by Targeting of the Ductal Epithelium with Adenovirus-Cre: A Novel Transgenic Mouse Model of Breast Cancer. Journal of Visualized Experiments, 2014, , .	0.3	20
112	Th1 cytokine interferon gamma improves response in HER2 breast cancer by modulating the ubiquitin proteasomal pathway. Molecular Therapy, 2021, 29, 1541-1556.	8.2	20
113	Using oncolytic viruses to ignite the tumour immune microenvironment in bladder cancer. Nature Reviews Urology, 2021, 18, 543-555.	3.8	20
114	Vascular Leukocytes: a Population with Angiogenic and Immunossuppressive Properties Highly Represented in Ovarian Cancer. , 2007, 590, 185-193.		20
115	Estradiol regulates MICA expression in human endometrial cells. Clinical Immunology, 2008, 129, 325-332.	3.2	19
116	Nanomolecular targeting of dendritic cells for ovarian cancer therapy. Future Oncology, 2009, 5, 1189-1192.	2.4	19
117	Anti-tumor immunity: Myeloid leukocytes control the immune landscape. Cellular Immunology, 2012, 278, 21-26.	3.0	19
118	Inhibition of Human Dendritic Cell ER Stress Response Reduces T Cell Alloreactivity Yet Spares Donor Anti-tumor Immunity. Frontiers in Immunology, 2018, 9, 2887.	4.8	19
119	Genomic and Single-Cell Landscape Reveals Novel Drivers and Therapeutic Vulnerabilities of Transformed Cutaneous T-cell Lymphoma. Cancer Discovery, 2022, 12, 1294-1313.	9.4	18
120	Modulating the tumor immune microenvironment as an ovarian cancer treatment strategy. Expert Review of Obstetrics and Gynecology, 2012, 7, 413-419.	0.4	16
121	Immunologic Consequences of Sequencing Cancer Radiotherapy and Surgery. JCO Clinical Cancer Informatics, 2019, 3, 1-16.	2.1	16
122	The Association of <i>MUC16</i> Mutation with Tumor Mutation Burden and Its Prognostic Implications in Cutaneous Melanoma. Cancer Epidemiology Biomarkers and Prevention, 2020, 29, 1792-1799.	2.5	15
123	Increased Hydrogen Peroxide Formation in Polymorphonuclear Leukocytes of IDDM Patients. Diabetes Care, 1998, 21, 326-327.	8.6	14
124	IL-33 delays metastatic peritoneal cancer progression inducing an allergic microenvironment. Oncolmmunology, 2019, 8, e1515058.	4.6	14
125	PD-L1 Expression Correlates With Young Age and CD8+ TIL Density in Poorly Differentiated Cervical Squamous Cell Carcinoma. International Journal of Gynecological Pathology, 2020, 39, 428-435.	1.4	14
126	Loss of <sc>microRNA</sc>â€21 leads to profound stromal remodeling and short survival in <sc>Kâ€Ras</sc>â€driven mouse models of pancreatic cancer. International Journal of Cancer, 2020, 147, 2265-2278.	5.1	14



#	ARTICLE	IF	CITATIONS
127	Abstract CT056: Durable complete responses to adoptive cell transfer using tumor infiltrating lymphocytes (TIL) in non-small cell lung cancer (NSCLC): A phase I trial. Cancer Research, 2020, 80, CT056-CT056.	0.9	14
128	T cell repertoire in peripheral blood as a potential biomarker for predicting response to concurrent cetuximab and nivolumab in head and neck squamous cell carcinoma. , 2022, 10, e004512.		14
129	Interference of Chylomicrons in Analysis of Platelets by Flow Cytometry. Thrombosis Research, 1998, 91, 49-52.	1.7	13
130	Breaking barriers for T cells by targeting the EPHA2/TGF- $\beta$ 2/COX-2 axis in pancreatic cancer. Journal of Clinical Investigation, 2019, 129, 3521-3523.	8.2	13
131	TIM-3 blockade enhances IL-12-dependent antitumor immunity by promoting CD8 <sup>+</sup> T cell and XCR1 <sup>+</sup> dendritic cell spatial co-localization. , 2022, 10, e003571.		13
132	Effect of cyclical intermittent hypoxia on Ad5CMVCre induced solitary lung cancer progression and spontaneous metastases in the KrasG12D <sup>+</sup> ; p53fl/fl; myristolated p110fl/fl ROSA-gfp mouse. PLoS ONE, 2019, 14, e0212930.	2.5	12
133	CD122-directed interleukin-2 treatment mechanisms in bladder cancer differ from $\beta$ PD-L1 and include tissue-selective $\beta$ T cell activation. , 2021, 9, e002051.		12
134	Olfactory Receptor OR2H1 Is an Effective Target for CAR T Cells in Human Epithelial Tumors. Molecular Cancer Therapeutics, 2022, 21, 1184-1194.	4.1	12
135	Good things come in small packages. OncoImmunology, 2012, 1, 968-970.	4.6	11
136	Humoral immune responses: Unsung heroes of the war on cancer. Seminars in Immunology, 2020, 49, 101419.	5.6	11
137	Effects of checkpoint kinase 1 inhibition by prexasertib on the tumor immune microenvironment of head and neck squamous cell carcinoma. Molecular Carcinogenesis, 2021, 60, 138-150.	2.7	11
138	Role of Vascular Leukocytes in Ovarian Cancer Neovascularization. , 2008, 622, 273-280.		11
139	c-Maf: a bad influence in the education of macrophages. Journal of Clinical Investigation, 2020, 130, 1629-1631.	8.2	11
140	The 12-CK Score: Global Measurement of Tertiary Lymphoid Structures. Frontiers in Immunology, 2021, 12, 694079.	4.8	10
141	The Cancer Epitope Database and Analysis Resource: A Blueprint for the Establishment of a New Bioinformatics Resource for Use by the Cancer Immunology Community. Frontiers in Immunology, 2021, 12, 735609.	4.8	10
142	Circulating Biomarkers of Inflammation and Ovarian Cancer Risk in the Nurses' Health Studies. Cancer Epidemiology Biomarkers and Prevention, 2021, 30, 710-718.	2.5	9
143	Size does not matter: commensal microorganisms forge tumor-promoting inflammation and anti-tumor immunity. Oncoscience, 2015, 2, 239-246.	2.2	9
144	Wide and deep learning for automatic cell type identification. Computational and Structural Biotechnology Journal, 2021, 19, 1052-1062.	4.1	8

#	ARTICLE	IF	CITATIONS
145	TLR5 signaling, commensal microbiota and systemic tumor promoting inflammation: the three parcae of malignant progression. <i>Oncolmunology</i> , 2015, 4, e1021542.	4.6	7
146	Cancer Moonshot Immuno-Oncology Translational Network (IOTN): accelerating the clinical translation of basic discoveries for improving immunotherapy and immunoprevention of cancer. , 2020, 8, e000796.		7
147	Methyltransferase inhibitors restore SATB1 protective activity against cutaneous T cell lymphoma in mice. <i>Journal of Clinical Investigation</i> , 2021, 131, .	8.2	6
148	Tumor Expression Quantitative Trait Methylation Screening Reveals Distinct CpG Panels for Deconvolving Cancer Immune Signatures. <i>Cancer Research</i> , 2022, 82, 1724-1735.	0.9	6
149	Racial Differences in the Tumor Immune Landscape and Survival of Women with High-Grade Serous Ovarian Carcinoma. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2022, 31, 1006-1016.	2.5	6
150	Harnessing the Effect of Adoptively Transferred Tumor-Reactive T Cells on Endogenous (Host-Derived) Antitumor Immunity. <i>Clinical and Developmental Immunology</i> , 2010, 2010, 1-11.	3.3	5
151	It never rains but it pours. <i>Cell Cycle</i> , 2011, 10, 368-369.	2.6	5
152	Reprogramming immune responses via microRNA modulation. <i>MicroRNA Diagnostics and Therapeutics</i> , 2014, 1, .	0.0	5
153	Myristoylated p110 $\alpha$ Causes Embryonic Death Due to Developmental and Vascular Defects. <i>Open Life Sciences</i> , 2015, 10, 461-478.	1.4	5
154	Estrogens drive myeloid-derived suppressor cell accumulation. <i>Oncoscience</i> , 2017, 4, 5-6.	2.2	5
155	Barriers and Opportunities for CAR T-Cell Targeting of Solid Tumors. <i>Immunological Investigations</i> , 2022, 51, 2215-2225.	2.0	5
156	Fibroblast activation protein, a potential diagnostic and therapeutic target for cancerâ€”reply. <i>Human Pathology</i> , 2014, 45, 1553-1554.	2.0	4
157	Pharmacologic Tumor PDL1 Depletion with Cefepime or Ceftazidime Promotes DNA Damage and Sensitivity to DNA-Damaging Agents. <i>International Journal of Molecular Sciences</i> , 2022, 23, 5129.	4.1	4
158	Î³Î³ T cells share the spotlight in cancer. <i>Nature Cancer</i> , 2022, 3, 657-658.	13.2	4
159	Local Hyperthermia Treatment of Tumors Induces CD8+ T Cell-Mediated Resistance Against Distal and Secondary Tumors. <i>Frontiers in Nanobiomedical Research</i> , 2016, , 309-347.	0.1	3
160	lluminating the Numbers: Integrating Mathematical Models to Optimize Photomedicine Dosimetry and Combination Therapies. <i>Frontiers in Physics</i> , 2019, 7, .	2.1	3
161	Evaluation of zone electrophoresis of serum proteins performed on the Helena Laboratories rapid electrophoresis analyser. <i>Scandinavian Journal of Clinical and Laboratory Investigation</i> , 1995, 55, 729-731.	1.2	2
162	Small but Mighty: Selected Commensal Bacterial Species Determine the Effectiveness of Anti-cancer Immunotherapies. <i>Immunity</i> , 2015, 43, 1037-1039.	14.3	2

#	ARTICLE	IF	CITATIONS
163	The prognostic and predictive implications of the 12-chemokine score in muscle invasive bladder cancer.. Journal of Clinical Oncology, 2021, 39, 466-466.	1.6	2
164	Trial in progress: Phase II study of stereotactic body radiation therapy and atezolizumab in the management of recurrent, persistent, or metastatic cervical cancer.. Journal of Clinical Oncology, 2019, 37, TPS5596-TPS5596.	1.6	2
165	Double Agents in the War on Cancer: Leukocytes Govern Ovarian Cancer Progression. Oncotarget, 2012, 3, 226-227.	1.8	2
166	T Cells in Ovarian Cancer. New England Journal of Medicine, 2003, 348, 1814-1814.	27.0	1
167	Clinical characteristics and prognostic factors of 70 patients with SÄ©zary syndrome: a single-institutional experience at Moffitt cancer center. Leukemia and Lymphoma, 2021, , 1-8.	1.3	1
168	68â€¦The prognostic and predictive implications of the 12-chemokine score in muslce invasive bladder cancer. , 2020, , .		1
169	Inflammatory and immune responses induced by nanomaterials: challenges and opportunities for future nanotherapies. Nanotechnology Perceptions, 2009, 5, 195-203.	0.2	1
170	Estradiol induces NKG2D ligand expression in human endometrial epithelium. FASEB Journal, 2008, 22, 853.10.	0.5	1
171	Expression of epigenetic pathway related genes in association with PD-L1, ER/PgR and MLH1 in endometrial carcinoma. PLoS ONE, 2022, 17, e0264014.	2.5	1
172	Oncolytic HSV Exerts Direct Antiangiogenic Activity in Ovarian Carcinoma. Journal of Immunotherapy, 2004, 27, S7.	2.4	0
173	Mycobacterium tuberculosis infection induces il12rb1 splicing to generate a novel IL-12RÎ²1 isoform that enhances DC migration. Journal of Experimental Medicine, 2010, 207, 897-897.	8.5	0
174	Editorial: A clear vision needs some balance. Journal of Leukocyte Biology, 2012, 92, 918-920.	3.3	0
175	Characterization of Novel Immune Checkpoint Receptors within the Breast Cancer Tumor Microenvironment. Journal of the American College of Surgeons, 2017, 225, S21.	0.5	0
176	COX-Prostaglandin Pathway Inhibition May Augment the Effects of Immunotherapy in Breast Cancer. Journal of the American College of Surgeons, 2020, 231, S34-S35.	0.5	0
177	Kindlinâ€³ gives patrolling monocytes a strong grip. Journal of Leukocyte Biology, 2020, 107, 879-881.	3.3	0
178	Cover Image, Volume 60, Issue 2. Molecular Carcinogenesis, 2021, 60, i.	2.7	0
179	SATB1 Expression Governs Follicular Helper T-cell-Triggered Tertiary Lymphoid Structure Assembly. SSRN Electronic Journal, 0, , .	0.4	0
180	Abstract LB-360: Fluorescence-based co-registration with protein markers reveals distinct cellular compartments for altered microRNA expression in solid tumors. , 2010, , .		0

#	ARTICLE	IF	CITATIONS
181	Mesothelin expression as a predictive biomarker of breast cancer outcomes.. Journal of Clinical Oncology, 2014, 32, 11119-11119.	1.6	0
182	Abstract A66: Tumor-associated neutrophils in early stage human lung cancer are not immunosuppressive, but exhibit an inflammatory phenotype and provide accessory signals for T cell activation. , 2015, , .		0
183	Abstract IA32: Commensal microorganisms and polymorphic mucosal surfaces determine the evolution of distal metastatic tumors. , 2016, , .		0
184	Abstract A02: The origin and role of APC-like hybrid tumor-associated neutrophils in early-stage human lung cancer. , 2016, , .		0
185	Abstract 3707: Tumor-associated neutrophils with antigen-presenting features in early-stage human lung cancer. , 2017, , .		0
186	Abstract SY01-02: Blockade of estrogen signaling boosts antitumor immunity by dwindling cancer-promoting myelopoiesis. , 2018, , .		0
187	Abstract 5719: Tumor-suppressive stromal activity of pro-fibrogenic microRNA-21 in initiation and progression of K-Ras-driven mouse models of pancreatic cancer. , 2020, , .		0
188	93â€¦Targeting sirt2 rescues the metabolic fitness and effector functions of tumor-reactive T cells within the metabolically restricted tumor microenvironment. , 2020, , .		0
189	280â€¦Both tumor intrinsic and extrinsic factors contribute to TIL resistance in lung cancer patients. , 2020, , .		0